Prognostic Role of Circulating Tumor DNA in Resectable Pancreatic Cancer (PROJECTION)

Ludwig Maximilian University of Munich

Status: Active, not recruiting

Conditions: Pancreas Cancer

Treatments: Other: Liquid Biopsy

Study type: Observational

Funder types: Other; Industry

Identifiers

NCT04246203

ML40429

Details and patient eligibility

About

This is a non-randomized, multicenter, non-interventional study in patients with resectable PDAC. The patients are allocated to two observation groups according preoperative presence of ctDNA (Group A) or absence of detectable ctDNA (Group B) as determined in a liquid biopsy. After successful surgery of their pancreatic tumor and completion of local histological evaluation, tissue samples will be analyzed with regard to their mutational status with. Within 14 days before start of adjuvant tumor therapy another liquid biopsy will be taken to reassess the level of ctDNA after surgery.

Patients will be monitored for disease recurrence according to harmonized, institutional standards using clinical, laboratory and (cross-sectional) imaging modalities. Accordingly, patients will be assessed every three months in the first eighteen months after surgery and every six months thereafter or based on clinical need for 36 months after the date of surgery Follow up will be documented until occurrence of relapse (or death if death occurs earlier than relapse/progression) for a maximum of 36 months after the date of surgery.

Enrollment: 200 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Adult patients ≥ 18 years of age
2. Pancreatic mass, suspicious of pancreatic cancer, deemed resectable and resection planned.
3. Patient deemed medically fit for adjuvant chemotherapy by the investigator
4. Patient's legal capacity to consent to study participation
5. Signed and dated informed consent to participate in the study

Exclusion criteria

1. Non-resectable disease as determined by a local tumor board
2. Metastatic pancreatic disease
3. Previous neoadjuvant chemotherapy
4. Previous neoadjuvant radiotherapy
5. Histology other than PDAC such as acinar, neuroendocrine, mixed histology etc. in the resection specimen
6. Malignant disease other than PDAC within previous year (exception: patients with adequately treated and completely resected basal cell or squamous cell skin cancer; in situ cervical, breast or prostate cancer within previous year may be included)

Trial design

200 participants in 2 patient groups

Group A

Description:

Patients are allocated to group A according to preoperative presence of detectable ctDNA.

Treatment:

Other: Liquid Biopsy

Group B

Description:

Patients are allocated to group B according to preoperative absence of detectable ctDNA.

Treatment:

Other: Liquid Biopsy